Abstract
Incorporation of PD-1 blockade into the treatment algorithms for hematologic malignancies is currently being pursued in multiple active clinical trials. Here we review the data on anti–PD-1 monoclonal antibodies to date and discuss ongoing and future clinical trials.
Original language | English (US) |
---|---|
Journal | Oncology (United States) |
Volume | 29 |
Issue number | 6 |
State | Published - Jun 15 2015 |
ASJC Scopus subject areas
- Oncology
- Cancer Research